AR160

AR160 is an investigational nano-immunoconjugate developed by the Mayo Clinic for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. The drug consists of albumin-stabilized paclitaxel nanoparticles (nab-paclitaxel) that are non-covalently coated with the anti-CD20 monoclonal antibody rituximab, resulting in a nanoparticle with a diameter of approximately 160 nm. This design utilizes rituximab as a targeting moiety to deliver the cytotoxic payload, paclitaxel, specifically to CD20-expressing B-cell lymphoma tissues. Developed in the laboratory of Dr. Svetomir N. Markovic, AR160 represents a novel biologic modality that combines chemotherapy with immunotherapy through nanotechnology. In a first-in-human Phase I clinical trial (LS1681), AR160 demonstrated promising clinical activity and a favorable safety profile, achieving responses at significantly lower doses of paclitaxel and rituximab compared to standard treatment regimens.

Other names

nab-paclitaxel/rituximab-coated nanoparticle AR160Abraxane/Rituximab 160nm Nanoparticle